Conditions: Interstitial Lung Disease Connective Tissue Disease
Keywords: Interstitial lung disease Connective tissue disease Scleroderma Rheumatoid arthritis Sjogren's syndrome Mixed connective tissue disease Dermatomyositis Polymyositis Systemic lupus erythematosis
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 5
Healthy volunteers: no

Brief summary:
The first objective of this protocol is to assess the tolerability and safety of N-acetylcysteine (NAC) in patients with connective tissue disease related interstitial lung disease (CTD-ILD).

Detailed description:
The investigators will assess tolerability and safety at scheduled intervals via standard of care physical exam findings, monitoring complete blood count, serum chemistry, and pulmonary function tests, along with patient reports of medication intolerance and change in symptoms of dyspnea.

Arms:
arm 1: This is an open label trial, all patient will be entered into one treatment arm.

Interventions: intervention 1: N-Acetylcysteine
Intervention descriptions: intervention 1: 600mg by mouth, three times daily for 12 months

Protocol document: